These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 32691849)

  • 1. Prevalence of thyroid eye disease in Graves' disease: A meta-analysis and systematic review.
    Chin YH; Ng CH; Lee MH; Koh JWH; Kiew J; Yang SP; Sundar G; Khoo CM
    Clin Endocrinol (Oxf); 2020 Oct; 93(4):363-374. PubMed ID: 32691849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Factors of Thyroid Eye Disease.
    Lee MH; Chin YH; Ng CH; Nistala KRY; Ow ZGW; Sundar G; Yang SP; Khoo CM
    Endocr Pract; 2021 Mar; 27(3):245-253. PubMed ID: 33655885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy.
    Edmunds MR; Boelaert K
    Thyroid; 2019 Apr; 29(4):557-562. PubMed ID: 30688164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of Diabetic and Nondiabetic Patients With Thyroid Eye Disease in the United States: A Claims-Based Analysis.
    Patel VK; Padnick-Silver L; D'Souza S; Bhattacharya RK; Francis-Sedlak M; Holt RJ
    Endocr Pract; 2022 Feb; 28(2):159-164. PubMed ID: 34781042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [LIFESTYLE ADJUSTMENT AS THERAPEUTIC TOOL IN THYROID EYE DISEASE].
    Vashdi I; Gur Z
    Harefuah; 2022 Apr; 161(4):223-227. PubMed ID: 35466606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of Graves' disease in patients with thyroid eye disease].
    Sviridenko NY; Sheremeta MS; Belovalova IM; Melnichenko GA
    Vestn Oftalmol; 2021; 137(6):128-135. PubMed ID: 34965078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The "Quiet TED"-A Special Subgroup of Thyroid Eye Disease.
    Iñiguez-Ariza NM; Sharma A; Garrity JA; Stan MN
    Ophthalmic Plast Reconstr Surg; 2021 Nov-Dec 01; 37(6):551-555. PubMed ID: 33782324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence, risk factors, and clinical features of thyroid-associated ophthalmopathy in multiethnic Malaysian patients with Graves' disease.
    Lim SL; Lim AK; Mumtaz M; Hussein E; Wan Bebakar WM; Khir AS
    Thyroid; 2008 Dec; 18(12):1297-301. PubMed ID: 19012471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of multimodal clinical biomarkers in the management of thyroid eye disease.
    Poon SHL; Cheung JJ; Shih KC; Chan YK
    Rev Endocr Metab Disord; 2022 Jun; 23(3):541-567. PubMed ID: 35066781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid-associated ophthalmopathy in Iranian patients.
    Kashkouli MB; Jam S; Sabzvari D; Ketabi N; Azarinia S; SeyedAlinaghi S; Mofid A
    Acta Med Iran; 2011; 49(9):612-8. PubMed ID: 22052145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins and thyroid eye disease (TED): a systematic review.
    Malboosbaf R; Maghsoomi Z; Emami Z; Khamseh ME; Azizi F
    Endocrine; 2024 Jul; 85(1):11-17. PubMed ID: 38194219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivation of Graves' Disease and Thyroid Eye Disease following COVID-19 Vaccination - A Case Report.
    Hung CW; Hung CH
    Ocul Immunol Inflamm; 2023 Aug; 31(6):1286-1290. PubMed ID: 36796028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Socioeconomic Disparities in the Presentation and Treatment of Graves' Disease and Thyroid Eye Disease.
    Vargason CW; Chelnis JG; Barahimi BI; Mawn LA
    Semin Ophthalmol; 2016; 31(4):409-14. PubMed ID: 27385363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparison of Observational Studies on Subfoveal Choroidal Thickness Measured with OCT according to the Level of Thyroid Eye Disease Activity-Systematic Review and Meta-Analysis.
    Kowalik-Jagodzińska M; Sobol M; Turno-Kręcicka A
    J Clin Med; 2023 Jul; 12(14):. PubMed ID: 37510836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monoclonal antibodies in the treatment of thyroid eye disease].
    Cheredanova VR; Poteshkin YE
    Vestn Oftalmol; 2021; 137(4):116-122. PubMed ID: 34410066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States.
    Smith TJ; Cockerham K; Lelli G; Choudhary C; Taylor S; Barretto N; Enstone A; Oliver L; Lynch J; Holt RJ
    JAMA Ophthalmol; 2023 Feb; 141(2):159-166. PubMed ID: 36580313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in newly diagnosed Graves' disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression.
    Ippolito S; Cusini C; Lasalvia P; Gianfagna F; Veronesi G; Gallo D; Masiello E; Premoli P; Sabatino J; Mercuriali A; Lai A; Piantanida E; Tanda ML; Bartalena L
    J Endocrinol Invest; 2021 Aug; 44(8):1707-1718. PubMed ID: 33346898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Onset or Deterioration of Thyroid Eye Disease After mRNA SARS-CoV-2 Vaccines: Report of 2 Cases and Literature Review.
    Mohamed A; Tzoulis P; Kossler AL; Dosiou C
    J Clin Endocrinol Metab; 2023 Mar; 108(4):979-985. PubMed ID: 36251747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computed tomography and magnetic resonance imaging approaches to Graves' ophthalmopathy: a narrative review.
    Luccas R; Riguetto CM; Alves M; Zantut-Wittmann DE; Reis F
    Front Endocrinol (Lausanne); 2023; 14():1277961. PubMed ID: 38260158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.